Detail akcie Bavarian Nordic online

Business Summary: Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Bavarian Nordic A/S revenues increased from DKR3.15B to DKR7.06B. Net income totaled DKR1.48B vs. loss of DKR347.4M. Revenues reflect Sale of goods - MVA-BN smallpox vaccine sale segment increase from DKR1.73B to DKR5.03B, Sale of goods - Rabipur/RabAvert segment increase of 32% to DKR1.16B, United States segment increase from DKR841.5M to DKR2.58B, Canada segment increase from DKR197.3M to DKR1.56B.